EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Chengqian Chen, Wei Guo, Xiaoyu Song, Xin Wan, Zhaoxia Li, Haotian Wang, Ou Bai

Frontiers in Oncology · 29.05.2026 · 16

DOI: 10.3389/fonc.2026.1855868 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 29.05.2026. Verfasst von Chengqian Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China. Die Arbeit nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hodgkin lymphoma (HL) is a B-cell–derived hematologic malignancy originating from germinal centre B cells. Owing to its remarkable sensitivity to chemotherapy and radiotherapy, HL has become one of the most curable adult malignancies. Over the past decades, treatment regimens such as ABVD and escalated BEACOPP, combined with radiotherapy, have achieved 5-year survival rates exceeding 90% in early-stage patients and long-term remission rates above 75% in advanced-stage disease. However, long-term toxicities associated with conventional therapies—including secondary malignancies, cardiovascular disease, pulmonary fibrosis, and infertility—have increasingly compromised survivors’ quality of life. Meanwhile, approximately 5%–10% of patients exhibit primary refractory disease, and 10%–30% eventually relapse.In recent years, the emergence of targeted and immunotherapeutic agents, particularly the anti-CD30 antibody–drug conjugate (brentuximab vedotin) and immune checkpoint inhibitors (e.g., PD-1 inhibitors), has profoundly reshaped the therapeutic landscape of HL. This review systematically summarises the epidemiological characteristics and biological foundations of HL, as well as the achievements and limitations of conventional therapies. We place particular emphasis on key clinical trial evidence in recent years and discuss paradigm shifts in four major areas: treatment de-escalation and toxicity reduction in frontline therapy, precision salvage strategies for relapsed/refractory HL, the evolving role of transplantation, and the application of precision medicine tools such as circulating tumour DNA (ctDNA) and molecular subtyping. We further explore how HL treatment is transitioning from a “cure-oriented” model focused solely on survival to a novel paradigm of “functional cure” that balances efficacy with long-term quality of life. We define “functional cure” as durable remission with minimal long−term toxicity, preserving organ function and quality of life—a unifying principle of modern HL management. Special attention is given to clinical decision-making in PD-1–exposed patients, emerging therapeutic targets, cellular therapies, and the growing role of real-world evidence. These insights aim to inform future individualised treatment strategies in HL.

Schlagwörter

Stichwörter der Autor:innen

Hodgkin lymphomaPD-1 inhibitorsbrentuximab vedotinctDNAfunctional cureprecision therapytumour microenvironment

Autor:innen und Institutionen

  • Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China.
  • Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, China.

Zitieren

APA

Chen, C., Guo, W., Song, X., Wan, X., Li, Z., Wang, H., & Bai, O. (2026). Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1855868

Vancouver

Chen C, Guo W, Song X, Wan X, Li Z, Wang H, et al. Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1855868

BibTeX
@article{Chen2026,
  author = {Chen, Chengqian and Guo, Wei and Song, Xiaoyu and Wan, Xin and Li, Zhaoxia and Wang, Haotian and Bai, Ou},
  title = {Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1855868}
}
Kostenlos starten →